| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
Department of Pediatric Endocrinology, Charité Children’s Hospital, Humboldt University Berlin, Augustenburger Platz 1, 13353 Berlin, Germany and 1 Institute of Experimental Endocrinology, Charité University Hospital, Humboldt University Berlin, Schumannstr. 20/21, 10117 Berlin, Germany
(Correspondence should be addressed to A Grueters; Email: annette.grueters{at}charite.de)
Objective: Thyroid hormones, besides having other functions, are known to be essential for the development of the human brain. Recently the monocarboxylate transporter 8 (MCT8) was identified as a thyroid hormone transporter which is expressed in different regions of the human brain. Here we describe in detail the clinical and biochemical features in response to thyroid hormone administration of a boy carrying an MCT8 mutation (A150V) in the second transmembrane domain.
Methods: To study the functional impact of the mutation we performed triiodothyronine (T3) uptake, immunofluorescence and dimerization studies.
Results: Thyroid hormone (L-thyroxine (LT4) and LT3) administration did not result in any significant clinical changes; however, with high doses of LT4, alone or in combination with T3, TSH suppression was achieved. We could show a robust uptake of 125I-T3 for wild type (WT) MCT8, whereas no specific uptake could be detected for the mutant A150V. Subcellular localization of WT and mutant MCT8 revealed a strong cell surface expression for the WT MCT8, in contrast to A150V, which is mostly retained intracellularly with only weak cell surface expression. We could also demonstrate for the first time that WT MCT8 as well as the mutant are able to form multimers.
Conclusion: Our findings open a wide field of possible interaction within the central nervous system and will help to understand the crucial role of MCT8 in early fetal brain development.
This article has been cited by other articles:
|
|
 |
|
  S. R. James, J. A. Franklyn, B. J. Reaves, V. E. Smith, S. Y. Chan, T. G. Barrett, M. D. Kilby, and C. J. McCabe Monocarboxylate Transporter 8 in Neuronal Cell Growth Endocrinology, April 1, 2009; 150(4): 1961 - 1969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Heuer and T. J. Visser Pathophysiological Importance of Thyroid Hormone Transporters Endocrinology, March 1, 2009; 150(3): 1078 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Wemeau, M. Pigeyre, E. Proust-Lemoine, M. d'Herbomez, F. Gottrand, J. Jansen, T. J. Visser, and M. Ladsous Beneficial Effects of Propylthiouracil plus L-Thyroxine Treatment in a Patient with a Mutation in MCT8 J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2084 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Sijens, L. A. Rodiger, L. C. Meiners, and R. J. Lunsing 1H Magnetic Resonance Spectroscopy in Monocarboxylate Transporter 8 Gene Deficiency J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1854 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jansen, E. C. H. Friesema, M. H. A. Kester, C. E. Schwartz, and T. J. Visser Genotype-Phenotype Relationship in Patients with Mutations in Thyroid Hormone Transporter MCT8 Endocrinology, May 1, 2008; 149(5): 2184 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jansen, E. C. H. Friesema, M. H. A. Kester, C. Milici, M. Reeser, A. Gruters, T. G. Barrett, E. E. Mancilla, J. Svensson, J.-L. Wemeau, et al. Functional Analysis of Monocarboxylate Transporter 8 Mutations Identified in Patients with X-Linked Psychomotor Retardation and Elevated Serum Triiodothyronine J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2378 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Dumitrescu, X.-H. Liao, R. E. Weiss, K. Millen, and S. Refetoff Tissue-Specific Thyroid Hormone Deprivation and Excess in Monocarboxylate Transporter (Mct) 8-Deficient Mice Endocrinology, September 1, 2006; 147(9): 4036 - 4043. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
